Wesbanco Bank Inc. Has $3.12 Million Stock Position in Danaher Co. (NYSE:DHR)

Wesbanco Bank Inc. cut its holdings in shares of Danaher Co. (NYSE:DHR) by 16.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,477 shares of the conglomerate’s stock after selling 2,467 shares during the quarter. Wesbanco Bank Inc.’s holdings in Danaher were worth $3,117,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ST Germain D J Co. Inc. grew its position in Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares in the last quarter. Godsey & Gibb Inc. grew its holdings in shares of Danaher by 3.0% during the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after acquiring an additional 42 shares in the last quarter. Nicholas Hoffman & Company LLC. increased its stake in shares of Danaher by 2.3% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock worth $439,000 after acquiring an additional 43 shares during the last quarter. Berger Financial Group Inc raised its holdings in shares of Danaher by 1.7% during the fourth quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock worth $582,000 after acquiring an additional 43 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its position in Danaher by 1.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after purchasing an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Linda Filler sold 3,928 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the sale, the director now directly owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,797 shares of company stock worth $18,039,944. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 2.0 %

NYSE:DHR opened at $268.56 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a market cap of $198.92 billion, a price-to-earnings ratio of 45.52, a P/E/G ratio of 4.62 and a beta of 0.83. The stock’s fifty day moving average price is $257.08 and its two-hundred day moving average price is $251.89.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS. On average, analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on DHR shares. The Goldman Sachs Group upped their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective on the stock. Evercore ISI decreased their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.